Eiger biopharmaceuticals, inc. (EIGR)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Operating activities
Net loss

-

-

-

-

-

-

-

-

-

-

-

0

-48,578

-

0

0

0

-

-

-

-

-

-

-

-

Net loss

-68,302

-70,252

-69,833

-68,361

-60,749

-52,391

0

0

0

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

91

68

61

59

56

54

45

44

43

41

0

0

0

-

-

-

-

11

414

246

203

153

0

0

0

Depreciation and amortization

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Amortization of debt securities discounts

384

467

559

573

544

426

247

25

3

53

0

0

0

-

-

-

-

-

-424

-534

-528

-393

0

0

0

Non-cash interest expense

737

723

734

726

671

592

493

413

391

366

266

171

73

685

0

0

0

-

2,005

865

630

388

0

0

0

Amortization of operating lease right-of-use assets

436

418

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Common stock issued under Product Development Agreement

223

226

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation

6,113

5,679

5,842

5,365

5,199

5,007

4,516

4,297

3,922

4,243

4,662

4,948

4,176

3,190

-1,204

-2,461

-1,537

227

4,324

5,253

4,903

3,319

0

0

0

Change in fair value of obligation to issue shares to Eiccose

-

-

-

-

-

-

-

-

-

-

-

-

-

204

0

0

0

-

-

-

-

-

-

-

-

Change in fair value of warrants liability

-

-

-

-

-

-

-

-

-

-

-

-

-

165

0

0

0

-

-

-

-

183

0

0

0

Loss on disposal of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Deferred rent

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

Change in operating assets and liabilities:
Prepaid expenses and other current assets

2,264

3,698

2,595

1,548

1,977

780

1,081

516

88

131

-129

-191

55

-326

0

0

0

-

-

-

-

-

-

-

-

Other assets

1,075

2,075

2,999

2,308

2,417

124

323

209

165

169

-76

-64

-31

89

0

0

0

-

-

-

-

-

-

-

-

Accounts payable

3,350

584

2,491

2,715

2,498

2,647

2,350

-30

-162

544

92

3,229

-2,875

699

0

0

0

-

-

-

-

-

-

-

-

Accrued liabilities

-952

5,610

5,494

3,115

3,639

2,110

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities

-445

-430

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued and other liabilities

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

Other long term liabilities

-

-

-

-

-

212

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-62,472

-63,614

-61,145

-60,261

-52,981

-42,671

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Investing activities
Prepaid expenses and other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-68

250

939

2,860

0

0

0

Accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,912

2,485

556

2,935

0

0

0

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-45,263

-

767

-1,308

1,918

-9,133

-46,618

-43,566

-37,477

-29,259

0

0

0

Purchase of debt securities available-for-sale

118,257

96,267

0

0

0

-

-

-

-

24,524

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of investment securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

90,659

0

0

0

Proceeds from maturities of debt securities available-for-sale

86,079

80,271

59,271

52,550

37,300

28,250

25,750

36,075

49,845

47,025

0

0

0

-

-

-

-

-

82,337

81,837

73,062

30,210

0

0

0

Cash received from merger transaction

-

-

-

-

-

-

-

-

-

-

-

-

-

28,018

0

0

0

-

-

-

-

-

-

-

-

Purchase of property and equipment

497

475

0

0

0

-

-

-

-

44

49

82

73

58

-137

-91

-41

44

425

625

621

739

0

0

0

Net cash provided by investing activities

-32,675

-16,471

-42,020

-24,896

-21,979

-29,085

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Financing activities
Proceeds from sale of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Net cash provided (used in) by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-34,560

-

-42,448

-34,225

-21,746

-44

80,191

28,628

-17,964

-61,188

0

0

0

Proceeds from borrowings in connection with term loan, net of issuance costs

-

6,627

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of accrued exit fee and second amendment fee

-

913

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Costs paid in connection with common stock offerings

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7,661

0

0

0

Repayment of term loan

-

1,667

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock upon stock option exercises

809

844

0

0

0

-

-

-

-

-

-

-

-

39

0

0

0

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock upon private placement, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

32,108

0

0

0

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock upon ESPP purchase

154

130

130

121

121

96

96

119

119

142

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of common stock upon offering at-the-market, net of issuance costs

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,233

45,007

45,064

95,028

0

0

0

Proceeds from issuance of common stock upon warrants exercises

-

-

-

-

-

-

-

-

-

-

-

-

-

7

0

0

0

-

-

-

-

-

-

-

-

Net cash provided by financing activities

54,369

58,196

105,644

110,255

105,120

100,983

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (decrease) increase in cash and cash equivalents

-40,778

-21,889

2,479

25,098

30,160

29,227

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

33,077

-

74,541

44,550

44,665

13,179

-10,848

51,608

51,582

96,979

0

0

0

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-46,746

-

32,860

9,016

24,837

4,001

22,725

36,670

-3,859

6,532

0

0

0

Conversion of warrant liability to common stock upon private placement

-

-

-

-

-

-

-

-

-

-

-

-

-

1,050

0

0

0

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock upon private placement, net of issuance cost

-

-

-

-

-

-

-

-

-

-

-

-

-

32,108

0

0

0

-

-

-

-

-

-

-

-

Non-cash net liabilities assumed in reverse merger

-

-

-

-

-

-

-

-

-

-

-

-

-

671

0

0

0

-

-

-

-

-

-

-

-

Conversion of convertible promissory note to common stock upon private placement

-

-

-

-

-

-

-

-

-

-

-

-

-

6,129

0

0

0

-

-

-

-

-

-

-

-

Conversion of preferred stock to common stock upon reverse merger

-

-

-

-

-

-

-

-

-

-

-

-

-

22,567

0

0

0

-

-

-

-

-

-

-

-

Interest paid

2,555

2,638

2,490

2,255

2,132

1,652

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-